Stock Analysis: Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology.

Overview

Sun Pharma Advanced Research Company Limited is a healthcare company based in Mumbai, India. The company is involved in the research and development of pharmaceutical products with a focus on various therapeutic areas such as oncology, neurodegeneration, ophthalmology, dermatology, and immunology.

Key Financial Statistics

• Current Price: 368.45 INR
• Market Cap: 119.96 Billion INR
• PE Ratio (Forward): 8.37
• EPS (Trailing): -11.33
• Debt to Equity Ratio: 4.28

Company Officers

The company officers include Mr. Anilkumar Raghavan, Mr. Chetan M. Rajpara, Mr. Siu-Long Yao, Mr. Jaydeep Issrani, Ms. Shanta Gupta, Dr. Nitin Dharmadhikari, Dr. Nitin K. Damle Ph.D., Mr. Yashoraj Zala, Mr. Vikram Ramanathan, and Dr. Venkata Palle.

Key Ratios and Margins

• Revenue Growth: -89.4%
• Gross Margins: 69.38%
• Operating Margins: -7.63%

Analyst Recommendations

• Recommendation: Buy
• Target High Price: 1370.0 INR
• Target Low Price: 1194.0 INR
• Target Mean Price: 1282.0 INR

Conclusion

Sun Pharma Advanced Research Company Limited is a key player in the drug manufacturing industry with a focus on specialty and generic products. Despite facing challenges such as negative revenue growth and negative operating margins, the company has a strong market presence and a favorable analyst recommendation of 'Buy'.